Membrane penetration enhancement of ibuprofen using supersaturation

International Journal of Pharmaceutics

Volumn 198, Issue 2, 2000, Pages 229-238

  Iervolino, M ^a   Raghavan, S L ^b   Hadgraft, J ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Diffusion; Hydroxpropyl cyclodextrin; Hydroxypropyl methyl cellulose; Ibuprofen; Silicone; Stability; Supersaturation

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ACETONITRILE; HYDROXYPROPYLMETHYLCELLULOSE; IBUPROFEN; PENETRATION ENHANCING AGENT; PROPYLENE GLYCOL; SILICONE; SOLVENT; WATER;

ARTICLE; ARTIFICIAL MEMBRANE; CONTROLLED STUDY; DIFFUSION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; PRIORITY JOURNAL; SATURATION; TECHNIQUE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA-CYCLODEXTRINS; CYCLODEXTRINS; DIFFUSION; DRUG STABILITY; IBUPROFEN; LACTOSE; METHYLCELLULOSE; OXAZINES; PERMEABILITY; SOLUBILITY;

EID: 0034607429     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00346-X     Document Type: Article

References (18)

1. Barry B.W. Dermatological Formulations. 1983;186-204 Dekker, New York.
2. Coldmann M.F., Poulsen B.J., Hoguchi T. Enhancement of percutaneous absorption rates by the use of volatile: non-volatile systems as vehicles. J. Pharm. Sci. 58:1969;1098-1102.
3. Davis A.F., Hadgraft J. Effect of supersaturation on membrane transport: 1. Hydrocortisone acetate. Int. J. Pharm. 76:1991;1-8.
4. Higuchi T Physical chemical analysis of percutaneous absorption process from creams and ointments. J. Soc. Cosmet. Chem. 11:1960;85-97.
5. Kondo S., Yamanaka C, Sugimoto I. Enhancement of transdermal delivery by superfluous thermodynamic potential. III: percutaneous absorption of nifedipine in rats. J. Pharmacobio-Dyn. 10:1987;743-749.
6. Loftsson T., Olafsdottir B.J., Bodor N. The effects of cyclodextrin on transdermal delivery of drugs. Eur. J. Pharm. Biopharm. 37(1):1991;30-33.
7. Loftsson T., Olafsdottir B.J., Fridriksdottir H., Jonsdottir S. Cyclodextrin complexation of NSAIDS: physicochemical characteristics. Eur. J. Pharm. Sci. 1:1993;95-101.
8. Masson M., Loftsson T., Masson G., Stefansson E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J. Contr. Release. 59:1999;107-118.
9. Megrab N.A., Williams A.C., Barry B.W. Oestradiol permeation through human skin and silastic membrane: effects of propylene glycol and supersaturation. J. Contr. Release. 36:1995;205-214.
10. Mura P., Bettinetti G.P., Manderioli A., Faucci M.T., Bramanti G., Sorrenti M. Interactions of ketoprofen and ibuprofen with β-cyclodextrins in solution and solid state. Int. J. Pharm. 166:1998;189-203.
11. Pellett M.A., Davis A.F., Hadgraft J. Effect of supersaturation on membrane transport: 2. Piroxicam. Int. J. Pharm. 111:1994;1-6.
12. Pellett M.A., Davis A.F., Hadgraft J. Supersaturated solutions evaluated with an in vitro stratum corneum tape stripping technique. Int. J. Pharm. 151:1997;91-98.
13. Poulsen B.J. Diffusion of drugs from topical vehicles: an analysis of vehicle effects. Adv. Biol. Skin. 12:1972;495-509.
14. Raghavan S.L., Trividic A., Davis A.F., Hadgraft J. Effect of cellulose polymers on supersaturation and in vitro membrane transport of hydrocortisone acetate. Int. J. Pharm. 193:2000;231-237.
15. Schwarb F.P., Imanidis G., Smith E.W., Haigh J.M., Surber C. Effect of concentration and saturation of topical Fluocinonide formulations on in vitro membrane transport and In vivo availability on human skin. Pharm. Res. 16:1999;917-923.
16. Torres-Labandeira J.J., Davignon P, Pitha J. J. Pharm. Sci. 80:1990;384-386.
17. Twist J.N., Zatz J.L. Influence of solvents of paraben permeation through idealized skin model membranes. J. Soc. Cosmet. Chem. 37:1986;429-444.
18. Uekama K., Ikegami K., Wang Z., Horiuchi Y, Hirayama F. Inhibitory effect of 2-hydroxypropyl-β-cyclodextrin on crystal growth of nifedipine during storage: superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J. Pharm. Pharmacol. 44:1992;73-78.